Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

The use of amisulpride in the treatment of acute psychosis

Authors Philippe Nuss, Martina Hummer, Cédric Tessier

Published 15 March 2007 Volume 2007:3(1) Pages 3—11

Philippe Nuss1, Martina Hummer2, Cédric Tessier1
1Université Pierre et Marie Curie- Paris6, INSERM U538, Department of Psychiatry, Faculty of Medicine, Pierre et Marie Curie, Paris, France; 2Department of Biological Psychiatry, Innsbruck University Hospital, Innsbruck, Austria
Abstract: The management of acute episodes in schizophrenia is frequently initiated in the psychiatric emergency department and requires rapid intervention to relieve distress and psychiatric symptoms. Both non-pharmacological and pharmacological interventions are needed to calm the patient and prevent potential harm to the patient or others. Treatment is a step-by-step process including management of behavioral symptomatology, diagnosis of potential organic causes, and evaluation of potential substance abuse. Better care is delivered if predefined standard operating procedures are adopted systematically. The ultimate goal of treatment is to establish a therapeutic alliance with the patient. Atypical antipsychotics given orally are recommended as a first-line treatment. As the treatment endpoint is calmness rather than sleep, a non-sedative antipsychotic agent is usually preferred. Drug tolerance is a major issue for the patient. Amisulpride is an effective atypical antipsychotic agent in this context. The optimal dose is 800 mg/day, which is effective on positive and negative symptoms and can be given from the first day with a low risk of extrapyramidal symptoms. Since drug–drug interactions are limited, agitation and anxiety may be controlled by short-term adjunctive therapy with benzodiazepines. In conclusion, amisulpride is an appropriate first-line treatment for the management of acute psychosis.

Keywords: amisulpride, schizophrenia, acute psychosis, efficacy, safety

Download Article [PDF] 

Readers of this article also read:

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis

Michael Pazianas, Cyrus Cooper, F Hal Ebetino, et al

Therapeutics and Clinical Risk Management 2010, 6:325-343

Published Date: 19 July 2010

Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis

Devi Mukkai Krishnamurty, Atoosa Rabiee, Sanjay B Jagannath, Dana K Andersen

Therapeutics and Clinical Risk Management 2009, 5:507-520

Published Date: 2 July 2009

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

Omar S Din, Penella J Woll

Therapeutics and Clinical Risk Management 2008, 4:149-162

Published Date: 8 February 2008

Drug management in chronic rhinosinusitis: identification of the needs

Jean-Baptiste HPJ Watelet, Philippe H Eloy, Paul B van Cauwenberge

Therapeutics and Clinical Risk Management 2007, 3:47-57

Published Date: 15 March 2007

Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia

R Lozano, MG Peralta Concha, A Montealegre, L de Leon, J Ortiz Villalba, et al

Therapeutics and Clinical Risk Management 2007, 3:149-155

Published Date: 15 March 2007

House dust mite control measures in the treatment of asthma

Gillian Vallance, Charles McSharry, Stuart Wood, Neil C Thomson

Therapeutics and Clinical Risk Management 2006, 2:347-354

Published Date: 15 December 2006

Optimizing use of opiates in the management of cancer pain

Mario Mandalà, Cecilia Moro, Roberto Labianca, Marco Cremonesi, Sandro Barni

Therapeutics and Clinical Risk Management 2006, 2:447-453

Published Date: 15 December 2006

Voriconazole in the management of nosocomial invasive fungal infections

Javier Pemán, Miguel Salavert, Emilia Cantón, Isidro Jarque, Eva Romá, et al

Therapeutics and Clinical Risk Management 2006, 2:129-158

Published Date: 15 June 2006